{"id":3026,"date":"2025-11-06T08:30:29","date_gmt":"2025-11-06T08:30:29","guid":{"rendered":"https:\/\/wallstreetendeavor.com\/?p=3026"},"modified":"2025-11-18T08:36:44","modified_gmt":"2025-11-18T08:36:44","slug":"global-drugmakers-rush-for-u-s-presence","status":"publish","type":"post","link":"https:\/\/wallstreetendeavor.com\/de\/pharmaceutical\/global-drugmakers-rush-for-u-s-presence\/","title":{"rendered":"Global Drugmakers Rush for U.S. Presence"},"content":{"rendered":"

The Trump administration\u2019s looming threat of a 100% tariff<\/span><\/a> on imported branded and patented drugs has global drugmakers announcing splashy US investments.<\/p>\n\n\n\n

While enforcement may be delayed for companies investing in U.S. manufacturing, the policy has already prompted fast-tracked projects, price adjustments, and even direct-to-consumer sales.<\/p>\n\n\n\n

Here\u2019s a look at what some of the biggest players are doing to mitigate supply-chain risks and reassure investors:<\/p>\n\n\n\n

Pfizer (PFE)<\/strong><\/h5>\n\n\n\n

Pfizer has committed $70 billion toward expanding its U.S.-based research, development, and manufacturing operations. The agreement secured a three-year grace period exempting its products from the potential tariffs, as the company accelerates domestic production and shifts inventories to mitigate risk.<\/p>\n\n\n\n

GSK (GSK.L)<\/strong><\/h5>\n\n\n\n

The London-based drugmaker is investing $30 billion over five years to expand its U.S. research and supply chain capabilities. GSK\u2019s focus is on building long-term manufacturing resilience and reducing exposure to global trade disruptions.<\/p>\n\n\n\n

Eli Lilly (LLY)<\/strong><\/h5>\n\n\n\n

Eli Lilly announced a $5 billion investment to build a major manufacturing facility in Virginia, the first of four planned U.S. plants. The project forms part of a broader $27 billion, five-year expansion to strengthen domestic supply chains and support future product launches.<\/p>\n\n\n\n

Johnson & Johnson (JNJ)<\/strong><\/h5>\n\n\n\n

J&J is raising its U.S. investment by 25%, bringing its total to $55 billion over the next four years. The company is building four new plants, including sites in Wilson and Holly Springs, North Carolina, to boost capacity and support future biologics manufacturing.<\/p>\n\n\n\n

Roche (ROG.S)<\/strong><\/h5>\n\n\n\n

Roche plans to invest $50 billion in U.S. operations over the next five years, including a $550 million expansion at its Indianapolis diagnostics hub and a new facility in Holly Springs, NC. The expansions, spanning Indiana, Pennsylvania, Massachusetts, and California are expected to create more than 12,000 jobs.<\/p>\n\n\n\n

AstraZeneca (AZN.L)<\/strong><\/h5>\n\n\n\n

AstraZeneca is committing $50 billion to U.S. manufacturing by 2030, anchored by a new drug substance facility in Virginia, its largest global investment to date. Additional expansions in Maryland, Massachusetts, California, Indiana, and Texas will further strengthen its U.S. supply network.<\/p>\n\n\n\n

Novartis (NOVN.S)<\/strong><\/h5>\n\n\n\n

Novartis plans to spend $23 billion over the next five years to build and expand 10 U.S. facilities, including six new manufacturing plants and an expanded San Diego R&D site. The initiative is expected to create more than 1,000 new jobs and significantly boost its domestic output.<\/p>\n\n\n\n

Sanofi (SASY.PA)<\/strong><\/h5>\n\n\n\n

The French pharmaceutical giant has pledged at least $20 billion through 2030 to grow its U.S. manufacturing capacity. Sanofi is expanding both its company-owned sites and partnerships with domestic manufacturers to stay resilient amid shifting trade conditions.<\/p>\n\n\n\n

Biogen (BIIB.O)<\/strong><\/h5>\n\n\n\n

Biogen is investing $2 billion to expand its North Carolina operations, adding capacity for gene-targeting therapies and automation. The company will soon operate eight facilities in the state, positioning it as a leader in advanced biologics manufacturing.<\/p>\n\n\n\n

Merck (MRK.N)<\/strong><\/h5>\n\n\n\n

Merck is one of the largest spenders, with a $3 billion pharmaceutical plant under construction in Virginia and a $1 billion biologics facility in Delaware. Combined with new expansions in North Carolina and Kansas, the company\u2019s total U.S. investment exceeds $70 billion, supporting more than 4,500 new jobs.<\/p>\n\n\n\n

AbbVie (ABBV.N)<\/strong><\/h5>\n\n\n\n

AbbVie is continuing a $10 billion U.S. expansion over the next decade. With 11 existing manufacturing sites, the company says it is \u201cfairly insulated\u201d from any near-term tariff impact thanks to proactive inventory management.<\/p>\n\n\n\n

Gilead Sciences (GILD.O)<\/strong><\/h5>\n\n\n\n

Gilead has announced $11 billion in new investment, bringing its total U.S. commitment to $32 billion. The company is building a pharmaceutical development and manufacturing hub in Foster City, CA, and developing two additional sites to expand its R&D footprint.<\/p>\n\n\n\n

For investors, the message is simple: big pharma isn\u2019t waiting for tariffs to hit.<\/strong> They\u2019re shifting cash and plants back to the U.S. to lock in growth and dodge risk.<\/p>\n\n\n\n

Earlier, Trump suggested tariffs could reach as high as 250%, but for now, these major branded-drug makers are clearly taking steps to stay ahead.<\/p>","protected":false},"excerpt":{"rendered":"

If you\u2019ve been watching the news, you might have noticed that big pharma isn\u2019t just waiting around, they\u2019re making moves to stay ahead of potential tariffs. Here\u2019s what investors should know.<\/p>","protected":false},"author":2,"featured_media":3027,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[48,32,55,57,7,63],"tags":[64,72,33,70,31],"class_list":["post-3026","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotech","category-pharma-general","category-pharma-industry","category-pharma-investments","category-pharmaceutical","category-worthy-endeavors","tag-biotech","tag-industry","tag-investing","tag-north-america","tag-pharmaceutical"],"acf":{"featured_video_oembed":"","featured_post_summary":"","post_source":""},"_links":{"self":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts\/3026","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/comments?post=3026"}],"version-history":[{"count":5,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts\/3026\/revisions"}],"predecessor-version":[{"id":3033,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts\/3026\/revisions\/3033"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/media\/3027"}],"wp:attachment":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/media?parent=3026"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/categories?post=3026"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/tags?post=3026"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}